Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma
Verteporfin with anti-PD1 exhibited antitumor potential by promoting a pro-inflammatory tumour microenvironment in melanoma. We believe that YAP1 acts as a master regulator of anti-PD1 resistance.
Authors
- János Tibor Fekete (ORCID: https://orcid.org/0000-0002-6672-6563)
- András Lánczky (ORCID: https://orcid.org/0000-0002-2600-7038)
- Balázs Győrffy (ORCID: https://orcid.org/0000-0002-5772-3766)
- Nabil V. Sayour (ORCID: https://orcid.org/0000-0003-2236-2881)
- Péter Ferdinandy (ORCID: https://orcid.org/0000-0002-6424-6806)
- Andrea Kovács (ORCID: https://orcid.org/0000-0002-1799-6743)
- Giampaolo Bianchini (ORCID: https://orcid.org/0000-0002-6790-6267)
- L Szabó (ORCID: https://orcid.org/0000-0003-4795-6862)
- Zoltán V. Varga (ORCID: https://orcid.org/0000-0002-2758-0784)
- Alberto Ocaña (ORCID: https://orcid.org/0000-0002-1067-9630)
- Szonja Kovacs (ORCID: https://orcid.org/0000-0001-6761-5550)
- Ágnes Paál
- Tamás Kovács (ORCID: https://orcid.org/0000-0003-4127-4545)
- Zsombor I. Hegedűs
Institutions
- Semmelweis University (HU)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- IRCCS Ospedale San Raffaele (IT)
- Montavid Thermodynamic Research Group (HU)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- University of Pecs (HU)
- HUN-REN Research Centre for Natural Sciences (HU)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1111/bph.70052
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap